Before Thanksgiving day, I posted a topic about MGD007. After reading some info I found it might not be as effective as I originally thought.
The other medicine CEA-TCB (RO6958688; RG7802) by Roche in phase 1 clinical trial is based on the same principle as MGD007:
MGD007 lets T-cells targets cancer cells with gpA33 x CD3 antigen while CEA-TCB lets T-cells targets cancer cells with CEA CD3 TCB.
Below is Roche's reports of phase 1 regarding drug's efficacy and side-effects, published in May 2017.
https://www.roche.com/investors/updates ... -05-18.htm
Our forum member Julie YW got the treatment of this drug in a phase 1 clinicial trial at MSCCC. The outcome was mixed.
The makers of both drugs will present detailed results in Jun 2018 in ASCO in Chicago.
In summary, while many patients including me are eager to participate in clinical trials of these two drugs, but now I do not feel excited after reading a lot of info.